semaglutide cardiovascular outcomes news 2025 october 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Semaglutide protects the heart beyond

Our program includes crucial guidance on nutrition and physical activity to help you build sustainable habits that last long after your treatment

Summer Kessel is a Registered Dietitian and Certified Specialist in Obesity and Weight Management

A 2025 Kaiser Family Foundation (KFF) poll suggests that about one in eight adults are taking a GLP-1 medication

Whats Next in the Litigation

Future research that elucidates the physiological effects of GLP-1 on glycogen metabolism and energy expenditure in humans would explain currently underinvestigated mechanisms that are likely to contribute to the clinical effects of these medications